Browse by Audience
Skip to content
Papers of the Week
Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine.
Abstract
A clinical ability to describe the response trajectory of patients receiving preventive migraine treatment could expedite and improve therapeutic management decisions. This post hoc analysis of the PROMISE-2 study evaluated the consistency and predictive power of Month 1 treatment response on later response in patients with chronic migraine.